Literature DB >> 18622026

Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression.

Weiwei Shan1, Prajakta S Palkar, Iain A Murray, Emily I McDevitt, Mary J Kennett, Boo Hyon Kang, Harriet C Isom, Gary H Perdew, Frank J Gonzalez, Jeffrey M Peters.   

Abstract

Peroxisome proliferator-activated receptor (PPAR) beta/delta-null mice exhibit exacerbated hepatotoxicity in response to administration of carbon tetrachloride (CCl(4)). To determine whether ligand activation of the receptor protects against chemical toxicity in the liver, wild-type and PPARbeta/delta-null mice were administered CCl(4) with or without coadministration of the highly specific PPARbeta/delta ligand GW0742. Biomarkers of liver toxicity, including serum alanine aminotransferase (ALT) and hepatic tumor necrosis factor (TNF) alpha mRNA, were significantly higher in CCl(4)-treated PPARbeta/delta-null mice compared to wild-type mice. Hepatic expression of TNF-like weak inducer of apoptosis receptor (TWEAKr) and S100 calcium-binding protein A6 (S100A6/calcyclin), genes involved in nuclear factor kappa B signaling, was higher in the CCl(4)-treated PPARbeta/delta-null mice compared to wild-type mice. GW0742 treatment resulted in reduced serum ALT concentration and lower expression of CCl(4)-induced TNF-alpha, S100A6, monocyte chemoattractant protein-1 (MCP1), and TWEAKr in wild-type mice, and these effects were not observed in PPARbeta/delta-null mice. Expression of TNF-alpha was higher in PPARbeta/delta-null primary hepatocytes in response to interleukin-1beta treatment compared to wild-type hepatocytes, but GW0742 did not significantly modulate TNF-alpha expression in hepatocytes from either genotype. While PPARbeta/delta-null hepatic stellate exhibited higher rates of proliferation compared to wild-type cells, GW0742 did not affect alpha-smooth muscle actin expression in these cells. Combined, these findings demonstrate that ligand activation of PPARbeta/delta protects against chemically induced hepatotoxicity by downregulating expression of proinflammatory genes. Hepatocytes and hepatic stellate cells do not appear to directly mediate the inhibitory effects of ligand activation of PPARbeta/delta in liver, suggesting the involvement of paracrine and autocrine events mediated by hepatic cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18622026      PMCID: PMC2527639          DOI: 10.1093/toxsci/kfn142

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  96 in total

Review 1.  The PPARs: from orphan receptors to drug discovery.

Authors:  T M Willson; P J Brown; D D Sternbach; B R Henke
Journal:  J Med Chem       Date:  2000-02-24       Impact factor: 7.446

2.  PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells.

Authors:  Yves Rival; Nathalie Benéteau; Thierry Taillandier; Mylène Pezet; Elisabeth Dupont-Passelaigue; Jean François Patoiseau; Didier Junquéro; Francis C Colpaert; André Delhon
Journal:  Eur J Pharmacol       Date:  2002-01-25       Impact factor: 4.432

3.  Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas.

Authors:  Mads Wichmann Matthiessen; Gitte Pedersen; Tatjana Albrektsen; Sven Adamsen; Jan Fleckner; Jørn Brynskov
Journal:  Scand J Gastroenterol       Date:  2005-02       Impact factor: 2.423

4.  Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding.

Authors:  P Escher; O Braissant; S Basu-Modak; L Michalik; W Wahli; B Desvergne
Journal:  Endocrinology       Date:  2001-10       Impact factor: 4.736

5.  The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation.

Authors:  Anna Planagumà; Joan Clària; Rosa Miquel; Marta López-Parra; Esther Titos; Jaime L Masferrer; Vicente Arroyo; Joan Rodés
Journal:  FASEB J       Date:  2005-05-04       Impact factor: 5.191

6.  Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome.

Authors:  Toshiya Tanaka; Joji Yamamoto; Satoshi Iwasaki; Hiroshi Asaba; Hiroki Hamura; Yukio Ikeda; Mitsuhiro Watanabe; Kenta Magoori; Ryoichi X Ioka; Keisuke Tachibana; Yuichiro Watanabe; Yasutoshi Uchiyama; Koichi Sumi; Haruhisa Iguchi; Sadayoshi Ito; Takefumi Doi; Takao Hamakubo; Makoto Naito; Johan Auwerx; Masashi Yanagisawa; Tatsuhiko Kodama; Juro Sakai
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-15       Impact factor: 11.205

7.  Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men.

Authors:  Ulf Risérus; Dennis Sprecher; Tony Johnson; Eric Olson; Sandra Hirschberg; Aixue Liu; Zeke Fang; Priti Hegde; Duncan Richards; Leli Sarov-Blat; Jay C Strum; Samar Basu; Jane Cheeseman; Barbara A Fielding; Sandy M Humphreys; Theodore Danoff; Niall R Moore; Peter Murgatroyd; Stephen O'Rahilly; Pauline Sutton; Tim Willson; David Hassall; Keith N Frayn; Fredrik Karpe
Journal:  Diabetes       Date:  2007-11-16       Impact factor: 9.461

8.  PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages.

Authors:  John S Welch; Mercedes Ricote; Taro E Akiyama; Frank J Gonzalez; Christopher K Glass
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-09       Impact factor: 11.205

9.  Inhibition of interleukin-1beta-induced group IIA secretory phospholipase A2 expression by peroxisome proliferator-activated receptors (PPARs) in rat vascular smooth muscle cells: cooperation between PPARbeta and the proto-oncogene BCL-6.

Authors:  Lucas Ravaux; Chantal Denoyelle; Claire Monne; Isabelle Limon; Michel Raymondjean; Khadija El Hadri
Journal:  Mol Cell Biol       Date:  2007-10-01       Impact factor: 4.272

10.  Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice.

Authors:  L Michalik; B Desvergne; N S Tan; S Basu-Modak; P Escher; J Rieusset; J M Peters; G Kaya; F J Gonzalez; J Zakany; D Metzger; P Chambon; D Duboule; W Wahli
Journal:  J Cell Biol       Date:  2001-08-20       Impact factor: 10.539

View more
  27 in total

Review 1.  The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention.

Authors:  Jeffrey M Peters; Yatrik M Shah; Frank J Gonzalez
Journal:  Nat Rev Cancer       Date:  2012-02-09       Impact factor: 60.716

Review 2.  Pharmacological agents for NASH.

Authors:  Vlad Ratziu
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-10-15       Impact factor: 46.802

Review 3.  Xenobiotic metabolism, disposition, and regulation by receptors: from biochemical phenomenon to predictors of major toxicities.

Authors:  Curtis J Omiecinski; John P Vanden Heuvel; Gary H Perdew; Jeffrey M Peters
Journal:  Toxicol Sci       Date:  2010-11-08       Impact factor: 4.849

Review 4.  Dissecting the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in colon, breast, and lung carcinogenesis.

Authors:  Jeffrey M Peters; Jennifer E Foreman; Frank J Gonzalez
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

Review 5.  Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation.

Authors:  Amanda Karolina Soares Silva; Christina Alves Peixoto
Journal:  Cell Mol Life Sci       Date:  2018-05-22       Impact factor: 9.261

Review 6.  Nuclear receptors and nonalcoholic fatty liver disease.

Authors:  Matthew C Cave; Heather B Clair; Josiah E Hardesty; K Cameron Falkner; Wenke Feng; Barbara J Clark; Jennifer Sidey; Hongxue Shi; Bashar A Aqel; Craig J McClain; Russell A Prough
Journal:  Biochim Biophys Acta       Date:  2016-03-04

7.  PPARβ/δ modulates ethanol-induced hepatic effects by decreasing pyridoxal kinase activity.

Authors:  Maryam Goudarzi; Takayuki Koga; Combiz Khozoie; Tytus D Mak; Boo-Hyon Kang; Albert J Fornace; Jeffrey M Peters
Journal:  Toxicology       Date:  2013-07-10       Impact factor: 4.221

8.  Regulation of Cytochrome P450 2B10 (CYP2B10) Expression in Liver by Peroxisome Proliferator-activated Receptor-β/δ Modulation of SP1 Promoter Occupancy.

Authors:  Takayuki Koga; Pei-Li Yao; Maryam Goudarzi; Iain A Murray; Gayathri Balandaram; Frank J Gonzalez; Gary H Perdew; Albert J Fornace; Jeffrey M Peters
Journal:  J Biol Chem       Date:  2016-10-20       Impact factor: 5.157

Review 9.  PPARalpha: energy combustion, hypolipidemia, inflammation and cancer.

Authors:  Sean R Pyper; Navin Viswakarma; Songtao Yu; Janardan K Reddy
Journal:  Nucl Recept Signal       Date:  2010-04-16

Review 10.  Identifying Novel Targets for Treatment of Liver Fibrosis: What Can We Learn from Injured Tissues which Heal Without a Scar?

Authors:  Michele T Pritchard; Jennifer M McCracken
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.